Company intelligence / Profile preview

Boston Therapeutics, Inc.

Manchester, New Hampshire, United Statesca.marketscreener.com ↗

Ownership: Public · BTHE
Development stage: Commercial

Overview

The company was developing PAZ320, a non-systemic chewable drug designed to reduce post-meal blood sugar in patients with Type 2 diabetes. As of 2013, they were preparing to initiate Phase 2 trials in France and planning for Phase 3 trials in 2014.

Therapeutic areas: EndocrinologyImmunology
Modalities: Small molecule drugscomplex carbohydrate chemistry
Industry: Biotech

Drug pipeline

2 assets

BTI320

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $0
Total revenue: $0
Enterprise value: $-1.8M

Beyond the preview

Go deeper on Boston Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boston Therapeutics, Inc..

Explore the full profile